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Huntington’s disease (HD) is a genetic, degenerative, and progressive central nervous system disease. It is characterized by motor
abnormalities and cognitive and psychiatric symptoms. Objective. To describe the precise degree of clinical severity of patients
with HD through a new neurocognitive assessment. Methods. Unprecedented battery of computerized tests, CNSVS (Central
Nervous System Vital Signs), was applied at three diﬀerent moments in 2008, 2009, and 2010. The accurate and reliable CNSVS
objectivelyprovidedthecognitivestateofpatientsandallowedfortheevaluationofdiseaseprogression.CaseReport.P.,26,female,
without any medication, with normal psychomotor development is a parent carrier of HD. In 2008, she was diagnosed with HD in
accordance with the Medical Genetics Laboratories. Conclusion. The tests may be useful to reveal the exact measure of the current
evolutionarystageofHDpatients,allowingformoreeﬃcientplanningoftreatmentandfutureprocedures,suchasthemedication,
therapy, and physical activity to be administered.
1.Introduction
Huntington’s disease [1] (HD) is a genetic progressive here-
dodegenerative disease of the central nervous system (CNS).
It is characterized by motor abnormalities and cognitive
and psychiatric symptoms. The motor abnormalities may
include muscle contractions, involuntary movements, loss of
balance, poor coordination, speech diﬃculties, and excessive
movements in stressful situations [1] .T h e r ei sc o g n i t i v e
diﬃculty in organizing thoughts to handle new situations,
tasks, loss of memory, and concentration. Psychiatric disor-
ders include depression, irritability, anxiety, and behavioral
changes [1].
The ﬁrst studies analyzed the inheritance and identiﬁed
families from New England [2]. HD is related to the IT 15
gene mutation [3], which encodes the protein Huntingtin
(HTT).
The mean age of onset of HD varies between 35 and 45.
If the age of the patient is 50 years or older (25% of cases),
HD is considered to be “late-onset HD”, and before age 202 Case Reports in Medicine
(approximately 10% of cases), it is deﬁned as “juvenile HD”,
which is the form that the case study patient has.
GeorgeHuntington[4]publishedhispaper“OnChorea”
that described the familial form of the disorder referred
to as “hereditary chorea”, which is a type of involuntary
movement. HD occurs in all races, both sexes, and in the
western population, with 30 to 70 individuals per million
being aﬀected. Using the diﬀerential diagnosis, it is not
diﬃcult to diﬀerentiate the conditions of many other HD
choreas. They must observe the mode of inheritance [4],
clinical course, prognosis, or ﬁndings in laboratory tests.
Diseasesofthebrainoftenaﬀectanindividual’sbehavior,
including the impairment of cognitive skills and the produc-
tion of neuropsychiatry symptoms. This report presents a
neurocognitive assessment through a case study of HD. It
uses a computerized neurocognitive test battery known as
Central Nervous System Vital Signs (CNSVS) [5] that was
applied in 2008, 2009, and 2010, with an interval of one
year between each assessment, in a patient with HD who
was not under any treatment (according to the patient’s own
decision).
The CNSVS was validated [6] reliable and suitable for
use as a screening tool that measures speed and accuracy of
basic mental functions. The test battery consisted of seven
CNSVS tests: (1) visual memory (memorize 15 words and
recognizethemattheend);(2)verbalmemory(memorize15
geometric ﬁgures and recognize them at the end); (3) sym-
bols (ﬁll in the blank spaces with the symbol corresponding
to a particular situation required in the proposed model);
(4) warning (the computer proposes issues: color and shape
or the individual should use the keyboards on the right or
left to ﬁnd the relevant answers); (5) perception of emotions
(the individual must match facial expressions with emotions
described below the ﬁgure proposed); (6) reasoning (various
geometric ﬁgures are proposed to ﬁnd associations and/or
coordination among them); (7) recall of the ﬁrst two tests,
verbal memory and visual memory.
The results of the CNSVS objectively provided the cog-
nitive state of patients and allowed the determination of
the progression of the disease. It may assist the physician
in clarifying the diagnosis and may be used periodically
to observe the emergence of deﬁcits in executive functions
[7].
Executive function [7] is a neuropsychological concept
that applies to the cognitive process responsible for the
execution and planning of activities including tasks, working
memory, sustained attention, and inhibition of impulses. In
addition,thememory’sverbal,visualandcompositeprocess-
ing speed, executive function, and sustained attention were
assessed. People with HD may show changes in executive
functions and possible functional manifestation of the brain
and the onset of new symptoms [7].
The aim of this case report was to describe the degree of
clinical severity of patients with HD through neurocognitive
assessment with an unprecedented battery of computerized
tests, CNSVS, to provide the cognitive state of patients and
allow for the evaluation of disease progression.
Table 1: Clinical levels of severity (CNSVS). The CNSVS [5]c o n -
tains ﬁve degrees of clinical severity based on a database with more
than 1900 subjects, aged between 8 and 90 years.
Above >110 High function and high capacity
Average 90–110 Normal function and normal capacity
Low Average 80–90 Sight deﬁcit and sight impairment
Low 70–79 Moderate deﬁcit and impairment possible
Very Low <70 Deﬁcit and impairment likely
2.CaseReport
P. is a 26-year-old female who is single, college graduate,
and currently does not work. She lives with her mother and
stepfather; her birth carried no complications, was breastfed
up to 8 months of age, experienced her menarche at 12 years,
began to be sexually active at the age of 16, and has normal
psychomotor development.
P. was diagnosed with HD in 2008 according to the
Medical Genetics Laboratories [8] detected through a blood
sample. The father carrier of HD died of medical complica-
tions at 40 years and had three more siblings with HD.
In May 2008, when the patient was 25 years old, a genetic
test [8] was conducted with a sample of blood. The result
showed a mutation detected. Repeats Allele I: 58 and Allele
II: 17.
According to the DNA [8], one expanded allele of 58
repeats was detected and the other allele size was within the
normal range for the laboratory. Thus, these results indicate
that the individual has the common genetic alteration found
in HD. Genetic counseling was recommended for at-risk
family members.
Analysis of the DNA from this individual has been used
to study the size(s) of the CAG [9] (trinucleotide repeat)
repeat region of the Huntington gene. The normal range is
considered to be up 28 copies of the repeat. Alleles with 27
repeats up to and including 35 repeats are considered to be
normal mutable alleles. To date, symptoms of HD have not
been reported in individuals with 35 or less repeats. Allele
sizes of 36 up to and including 38 repeats are considered to
be Huntington alleles with reduced penetrance. HD alleles
(mutations) are 40 repeats and greater. The reported sizes
for large expansions are approximations due to the precision
of the size measurements using current technology. The
genotype-phenotype correlations are not precise enough to
be used clinically [9].
From diagnosis until the present time, the patient did
not use any medication for HD. The family was advised
to seek medical treatment and did so by consulting several
specialists. The patient decided not to start treatment with
medication despite medical advice.
At 25, P. began to present diﬃculties in dealing with new
situations, such as performing daily tasks. Also, she displayed
a lack of concentration, coordination, mood swings, and
some involuntary movements.
The patient sought treatment with complaints of depres-
sion and diﬃculty with attention and concentration. Then,
P. was invited to participate in the study with CNSVS so thatCase Reports in Medicine 3
Table 2: Dashboard neurocognitive. Test Results CNSVS the years 2008, 2009, and 2010.
Subject: P. Percentile range >74 25−74 9–24 2–8 <2
Ages: 25, 26, 27 Standard score range >109 90–109 80–89 70–79 <70
Proﬁle
Scores Subject score Standard score Percentile Above Average Low Average Low Very Low
08 09 10 08 09 10 08 09 10 08 09 10 08 09 10 08 09 10 08 09 10 08 09 10
Composite memory 102 87 79 103 75 59 58 5 1 X X X
Verbal memory 52 45 42 97 71 61 42 3 1 X X X
Visual memory 50 42 37 107 85 71 68 16 3 X X X
Processing speed 34 45 31 62 75 58 1 5 1 X X X
Executive function 47 46 44 94 93 90 34 32 25 X X X
Social acuity 7 5 6 9 2 8 08 63 0 9 1 8 X X X
Reasoning 1 1 −17 6 7 6 6 9 5 5 2 X X X
Sustained attention 22 27 22 88 96 88 21 40 21 X X X
Working memory 5 9 6 8 1 9 58 41 0 3 7 1 4 X X X
∗Additional data 1 1 1 2 223 3 3 4 4444444 4 444444
Obs. 2008 (08); 2009 (09); 2010 (10).
Reaction time (milliseconds). In 2008—1171; In 2009—1180; In 2010—1315.
Total test time: 2008 (20:44min/sec); 2009 (22:24min/sec); 2010 (21:48min/sec).
∗Additional data:
(1) Subject scores: computed from the raw score calculations using the data values of the individual subtests and are simply the number of correct responses,
incorrect responses, and reaction times.
(2) Standard score: In CNSVS the average standard score of the group is 100 and standard deviation is 15.
(3) Scale of 1 to 100.
(4) Normative scores.
we could assess the degree of impairment in her executive
functions. The patient signed the informed consent and was
made aware of all procedures, and the study was approved
by the Ethics Committee for Research of the Institute of
Psychiatry (IPUB), Federal University of Rio de Janeiro
(UFRJ).
3.RelevanceandOriginality
Clinicians and researchers, with the help of neurocognitive
tests, accurately assessed the pathology of neurological
patients and quantitatively measure the health of the higher
functions of the brain and CNS.
4. Results
The absence of medication during the evaluation period
allowedustoanalyzetheevolutionaryaspectsoftheirclinical
and mental function. All tests were applied using the same
psychologist, oﬃce environment, and evaluator, with the
same level of cooperation from the patient.
Table 1 contains ﬁve levels of clinical severity from the
CNSVS [5] tests, based on a database with more than
1900 subjects and aged between 8 and 90 years. The
levels are classiﬁed as follows: Above: >110 (high function
and high capacity); Average: 90–110 (normal function and
normal capacity; Low Average: 80–90 (sight deﬁcit and sight
impairment); Low: 70–79 (moderate deﬁcit and impairment
possible); Very Low: <70 (deﬁcit and impairment likely).
Table 2 contains the instrument panel regarding neu-
rocognitive assessments 2008, 2009, and 2010. The test
results of the CNSVS reported in Table 2 are that the patient
did not achieve any results categorized as “Above” in the tests
from 2008, 2009, and 2010, which indicates that she did not
display high function or high capacity in the proposed tasks.
As shown in Table 2, the patient’s verbal and visual
memory were “Average” in 2008. In 2009, the patient’s
composite and verbal memory had declined to “Low”, in
2010, the patient’s composite and verbal memory were
“Very Low”, representing injury unlike the results for visual
memory, which only showed a moderate deﬁcit.
The patient’s processing speed was “Very Low” in 2008
and improved to “Low” in 2009 but in 2010 was reduced to
“Very Low”, showing deﬁcits and probable injury.
The patient’s executive function remained “Average” in
2008, 2009, and 2010, showing normal function and capabil-
ities.Hersocialacuityin2008was“Average”,andin2009and
2010, it was “Low Average” showing a slight deﬁcit and slight
impairment.
In 2008 and 2009, the patient’s ability to reason was
already“Low”anddecayedabitin2010to“VeryLow”,which
indicates probable deﬁcits and impairment. The patient’s
ability to sustain attention in 2008 was “Low Average” and
in 2009 recovered to “Average” but returned in 2010 to
“Low Average”, indicating a slight deﬁcit and impairment.
Similarly her working memory was “Low Average” in 2008
and recovered to “Average” in 2009 but returned in 2010 to
“Low Average”, indicating a slight deﬁcit and impairment.4 Case Reports in Medicine
5. Discussion
Brain injuries [10] often produce the loss of cognitive skills,
neuropsychiatry symptoms, and behavioral changes. The
preciseknowledgeofthepresenceandcharacteristicsofthese
manifestations may help in the diagnosis and neurological,
psychological, and psychiatric management and care in
patients with HD.
In our case study, we observed a signiﬁcant decrease of
cognitive and social function in the patient studied, which
contributed to a loss of social, occupational, and impairment
in the quality of life. The CNSVS [5] may help clinicians to
assess cognitive function of the individual and to accurately
identify their symptoms, impairments, and comorbidities.
Studies [11] on cognitive ability (thinking, judging,
and memory) are necessary to further our knowledge of
diseases such as HD, a degenerative disease with symptoms
that hinder emotional growth and development during its
progression and evolution due to a loss of cells in the basal
ganglia [11].
The possibility of a step-by-step follow-up is necessary
because the onset of symptoms allows us [12]t om o r e
eﬃciently assign immediate therapies targeted to speciﬁc
deﬁcits and, therefore, oﬀers a possible opportunity to slow
the development of HD.
Only in recent decades have researchers [13] begun to
study cognitive deﬁcits and neurological disorder at the
molecular level. What emerged from these studies [12]w a s
how the cells within the CNS communicate with each other
during the process of learning.
Recall that our study had a limited time period (2008–
2010) taking advantage of the period in which the patient
did not use medication to not interfere in the results. We
recommend a possible use of this tool (CNSVS) in long-term
clinicaltrialsandwithlargersamplesandalsocomparedwith
othercognitivetests.WeknowthatHuntington’sdiseasemay
have a broader course of 10–20 years.
Consider it relevant to the use of computerized tests
that allow to accurately assess the patient’s reaction time to
disease progression related to executive functions. That is,
with this type of test, periodically we see the emergence or
absence of deﬁcits in these functions.
6. Conclusion
The study of the degree of clinical severity through CNSVS
may be very important for measuring cognitive disturbances
[14, 15] in HD patients, helping the clinician to more
eﬀectively plan the treatment and procedures, such as phar-
macological treatment, psychotherapy, and physical activity
to be administered.
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